Potential risks of nitric oxide inhibition in spinal cord injury.
Vaziri
Nosratola D
ND
Division of Nephrology and Hypertension, University of California Irvine Medical Center, Orange, CA 92868, USA. ndvaziri@uci.edu
D050197:Atherosclerosis / Q000139:chemically induced / Q000503:physiopathology; D001794:Blood Pressure / Q000187:drug effects* / Q000502:physiology; D002543:Cerebral Hemorrhage / Q000139:chemically induced / Q000503:physiopathology; D004791:Enzyme Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D007024:Hypotension, Orthostatic / Q000188:drug therapy* / Q000503:physiopathology; D007262:Infusions, Intravenous; D019331:NG-Nitroarginine Methyl Ester / Q000009:adverse effects* / Q000627:therapeutic use; D009569:Nitric Oxide / Q000037:antagonists & inhibitors* / Q000502:physiology; D019001:Nitric Oxide Synthase / Q000037:antagonists & inhibitors / Q000502:physiology; D015539:Platelet Activation / Q000187:drug effects / Q000502:physiology; D011782:Quadriplegia / Q000188:drug therapy* / Q000503:physiopathology; D012307:Risk Factors; D013119:Spinal Cord Injuries / Q000188:drug therapy* / Q000503:physiopathology; D013564:Sympathetic Nervous System / Q000503:physiopathology
D004791:Enzyme Inhibitors; D009569:Nitric Oxide; D019001:Nitric Oxide Synthase; D019331:NG-Nitroarginine Methyl Ester